In order to test whether the TP53 mutational status of AML blasts might impact the efficacy of CAR T-cell therapies, we took advantage of a recently developed isogenic human MOLM13 AML cell line model that was CRISPR/Cas9-engineered to express an allelic series of the six most common TP53 missense mutations, null as well as wild-type alleles (Boettcher et al, 2019). This evidence concerns the gene TP53 and acute myeloid leukemia.